Proteases and protease inhibitors in tumor progression
- PMID: 9433492
- DOI: 10.1007/978-1-4615-5391-5_9
Proteases and protease inhibitors in tumor progression
Abstract
Our understanding of the role of matrix degrading proteases in cancer has dramatically expanded over the last two decades. From correlative observations linking proteases to cancer progression, we have accumulated evidence supporting a causal role for proteases in various steps of tumor progression and have become increasingly aware of the complex interactions that exist among proteases. Specific natural inhibitors of these proteases have also been identified and their role as potent cytostatic agents in cancer has been suggested. In this article some of the concepts on the role of proteases in cancer are discussed and examples of cooperation between matrix metalloproteinases and the plasmin/plasminogen activators system are presented. The role of protease inhibitors such as tissue inhibitor of metalloproteinases-2 (TIMP-2) and plasminogen activator inhibitor-2 (PAI-2) as inhibitors of tumor growth, invasion and metastasis is discussed.
Similar articles
-
Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression.Enzyme Protein. 1996;49(1-3):72-84. doi: 10.1159/000468617. Enzyme Protein. 1996. PMID: 8796998 Review.
-
Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells.J Cell Physiol. 1996 May;167(2):333-40. doi: 10.1002/(SICI)1097-4652(199605)167:2<333::AID-JCP18>3.0.CO;2-8. J Cell Physiol. 1996. PMID: 8613475
-
Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.Jpn J Cancer Res. 1995 Jun;86(6):568-76. doi: 10.1111/j.1349-7006.1995.tb02436.x. Jpn J Cancer Res. 1995. PMID: 7622422 Free PMC article.
-
Protease inhibitors: role and potential therapeutic use in human cancer.Eur J Cancer. 1994;30A(14):2170-80. doi: 10.1016/0959-8049(94)00460-m. Eur J Cancer. 1994. PMID: 7857719 Review.
-
Proteases and their inhibitors in human brain tumours: a review.Anticancer Res. 1997 Nov-Dec;17(6B):4151-62. Anticancer Res. 1997. PMID: 9428349 Review.
Cited by
-
Activity-based protein profiling: the serine hydrolases.Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14694-9. doi: 10.1073/pnas.96.26.14694. Proc Natl Acad Sci U S A. 1999. PMID: 10611275 Free PMC article.
-
Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets.J Biol Chem. 2011 Feb 4;286(5):4027-42. doi: 10.1074/jbc.M110.184994. Epub 2010 Dec 3. J Biol Chem. 2011. PMID: 21131358 Free PMC article.
-
Cystatin C deficiency in human atherosclerosis and aortic aneurysms.J Clin Invest. 1999 Nov;104(9):1191-7. doi: 10.1172/JCI7709. J Clin Invest. 1999. PMID: 10545518 Free PMC article.
-
Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients.BMC Immunol. 2009 Jun 2;10:34. doi: 10.1186/1471-2172-10-34. BMC Immunol. 2009. PMID: 19490613 Free PMC article.
-
Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.Blood. 2006 May 1;107(9):3693-9. doi: 10.1182/blood-2005-04-1505. Epub 2006 Jan 12. Blood. 2006. PMID: 16410451 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous